← Products & brands

RetinaLyze, Denmark

RetinaLyze AI retinal screening

AI screening of retinal photographs for signs of diabetic retinopathy, age-related macular degeneration and glaucoma, with results in moments and built-in telemedicine.

RetinaLyze AI analysing a retinal fundus photograph

At a glance

Retinal screening AI · RetinaLyze, Denmark

Regular eye screening protects sight, and AI makes it possible to screen many more people. RetinaLyze analyses fundus photographs and returns a result within moments, so diabetes centres, primary care, optometry and eye clinics can screen at scale.

  • Screens for signs of diabetic retinopathy, AMD and glaucoma
  • Results within moments of upload
  • Image adequacy check at capture
  • OCT analysis support

Overview

RetinaLyze System A/S is a Danish company whose algorithms and services are CE marked and clinically validated. Capnova brings RetinaLyze to healthcare providers in the region with set-up, training and support.

Technology

RetinaLyze screens colour fundus images for signs of diabetic retinopathy, age-related macular degeneration and glaucoma, and checks image adequacy at the time of capture.

It also supports OCT analysis and includes the Advanced Glaucoma Progression AI with the Glaucoma Index of Progression (GIP) to track change over time.

The platform is web-based with end-to-end encryption. A telemedicine module shares images with specialists, and the system can be accessed online or integrated with existing healthcare software.

Applications

  • Diabetes centres and endocrinology clinics
  • Primary care and polyclinics
  • Ophthalmology and optometry clinics
  • Community and pharmacy screening
  • Occupational and corporate health
  • Remote and telemedicine programmes

Key features

  • Screens for signs of diabetic retinopathy, AMD and glaucoma
  • Results within moments of upload
  • Image adequacy check at capture
  • OCT analysis support
  • Glaucoma Index of Progression for tracking
  • Telemedicine module for specialist review
  • Web-based and end-to-end encrypted
  • CE marked and clinically validated

Technical data

RetinaLyze technical specifications

From the manufacturer's published information. Capnova confirms the current configuration and local registration status before every proposal.

Conditions screenedSigns of diabetic retinopathy, age-related macular degeneration and glaucomaRetinaLyze
InputsColour fundus photographs; OCT scansRetinaLyze
Glaucoma trackingAdvanced Glaucoma Progression AI with Glaucoma Index of Progression (GIP)RetinaLyze
PlatformWeb-based, end-to-end encryption, telemedicine moduleRetinaLyze
IntegrationOnline access or integration with existing healthcare softwareNICE MIB265
RegulatoryCE marked; clinically validatedRetinaLyze
Fundus camerasConfirmed for each site

Certifications & evidence

  • RetinaLyze algorithms and services are CE marked and clinically validated.
  • Evaluated in real-world diabetic retinopathy screening at Steno Diabetes Center North Jutland, Denmark (Journal of Personalized Medicine, 2023) and reviewed in the NICE Medtech Innovation Briefing on AI for diabetic retinopathy (MIB265, 2023).

Documents & downloads

Questions

Common questions about RetinaLyze AI retinal screening

We supply, install and support it for hospitals and clinics in the UAE (Dubai, Abu Dhabi, Sharjah), Saudi Arabia (Riyadh, Jeddah, Dammam), Qatar, Kuwait, Oman, Bahrain and Egypt.

How much does AI diabetic retinopathy screening cost?

Pricing depends on screening volumes and the modules used (fundus, OCT, glaucoma progression). Capnova sends a quotation after reviewing your screening programme.

How does AI diabetic retinopathy screening work?

A fundus camera captures a colour photograph of the retina and RetinaLyze analyses it for signs of diabetic retinopathy, age-related macular degeneration and glaucoma, returning a result within moments of upload and checking image adequacy at capture.

Does RetinaLyze work with OCT and fundus cameras?

RetinaLyze screens colour fundus photographs and also supports OCT analysis, including the Advanced Glaucoma Progression AI with the Glaucoma Index of Progression (GIP).

Who uses AI retinal screening?

Diabetes centres and endocrinology clinics, primary care and polyclinics, ophthalmology and optometry clinics, community and pharmacy screening, occupational health and telemedicine programmes.

Is RetinaLyze available in the UAE and Saudi Arabia?

Yes. Capnova Medical Solutions brings RetinaLyze to healthcare providers in the UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and Egypt, with set-up, training and support.

Get a quote for RetinaLyze

Tell us about your facility and we will recommend the right quantity and configuration.